The promise of combining inhibition of PI3K and PARP as cancer therapy

Cancer Discov. 2012 Nov;2(11):982-4. doi: 10.1158/2159-8290.CD-12-0433.

Abstract

Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • BRCA1 Protein / biosynthesis*
  • BRCA2 Protein / biosynthesis*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology*
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Genes, BRCA1*
  • Humans
  • Phosphoinositide-3 Kinase Inhibitors*
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • BRCA1 Protein
  • BRCA2 Protein
  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors